ReviewZhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi2026
[Advances in the prevention and treatment of acute graft-versus-host disease with cellular and novel targeted immunotherapy].
Review in Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Acute graft-versus-host disease (aGVHD) remains a severe complication following allogeneic hematopoietic stem cell transplantation, and traditional corticosteroid therapy often demonstrates limited efficacy. This review highlights the recent advances in cellular and targeted immunotherapies for aGVHD. Mesenchymal stem cells show considerable efficacy in steroid-resistant aGVHD and are already in clinical use. Regulatory T cells (Treg), including CAR-engineered Tregs, effectively induce immune tolerance and reduce GVHD incidence. Targeted agents, such as CTLA-4 fusion proteins and α4β7 integrin antibodies, mitigate severe aGVHD by blocking immune activation or T-cell homing. Additionally, tissue-repair factors (e.g., IL-22, GLP-2 analogs) and immunomodulatory molecules (e.g., α1-antitrypsin) offer novel strategies that combine tissue protection with immunomodulation. Collectively, these innovative therapies are driving aGVHD treatment toward precision, high efficacy, and low toxicity, demonstrating a promising clinical potential.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.